Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PD of Sodium Zirconium Cyclosilicate in Healthy Chinese Subjects
NCT03283267Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium zirconium cyclosilicate in hyperkalemia (2 arms), sponsored by AstraZeneca. Primary endpoint: Mean change from baseline to ZS treatment period in urine potassium excretion. Started Oct 2017; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03283267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283267.